- Alibaba, with a lower market cap than Palantir, offers a cheaper valuation, making it an appealing AI stock. As China aims to lead in AI, Alibaba’s growth is expected to accelerate, positioning it as a key player in cloud services and AI technology development.
- ASML, dominating the EUV market, boasts a more attractive valuation compared to Palantir. With a near monopoly in EUV technology critical for AI chips, ASML expects significant revenue growth by 2030, making it a promising stock to watch over the next three years.
- UnitedHealth Group, facing temporary challenges, is expected to rebound and surpass Palantir’s market cap by 2028. Despite medical cost issues and DOJ investigations, UnitedHealth’s strategic adjustments and historical resilience make it a valuable investment opportunity with strong potential for growth.
Read more at Nasdaq: Prediction: 3 Magnificent Stocks That’ll Be Worth More Than Palantir by 2028